Japan’s Ministry of Health, Labour and Welfare (MHLW) has set the initial reimbursement price for Eisai Co., Ltd./Biogen, Inc.’s Alzheimer's drug Leqembi (lecanemab) under the national health insurance (NHI) scheme, paving the way for a market launch in the country on 20 December.
The intravenously administered, amyloid beta-targeting antibody, approved for slowing the progression of mild cognitive impairment and mild dementia due to...